Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза I–II Россия

Tivantinib; Placebo; Cetuximab; Irinotecan

A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy

Номер протоколаARQ197-A-U252
ФазаФаза I–II
Участников по плану — во всех странах исследования131
Сроки26.01.2010 — 20.02.2015
Начало: 26 января 2010Окончание: 20 февраля 2015
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01075048/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Совмещённое исследование фаз Фаза I–II: Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного. Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 131 чел. во всех странах исследования.
  • Плановая дата окончания (02.2015) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • Состояние пациента (ECOG)0–1
  • Биомаркеры в критерияхKRAS
  • Опухольнужен измеримый очаг (RECIST)
  • Стадияметастатическая (IV), местно-распространённая (III)
  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 16 · невключение: 19

Критерии включения

  • Participants with surgically unresectable locally advanced or metastatic disease who have received one prior line of chemotherapy. (The Phase 1 portion of the study will be open for enrollment for subjects who received 1 or more prior therapies). Both relapsed and refractory CRC are allowed.
  • All participants must express the wild-type form of the gene KRAS.
  • Measurable disease according to RECIST (Response Evaluation Criteria In Solid Tumors) criteria, Version 1.1.
  • Male or female >= to 18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE, Version 4.0, grade <= to 1.
  • Adequate bone marrow, liver, and renal functions, defined as:
  • Hemoglobin >= to 9.0 g/dL (transfusion and/or growth factor support allowed).
  • Absolute neutrophil count (ANC) >= to 1.5 x 10\^9/L.
  • Platelet count >= to 75 x 10\^9/L.
  • Serum creatinine <= to 1.5 x upper limit of normal (ULN) or creatinine clearance >= to 60 mL/min.
  • Alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase <= to 2.5 x ULN in subjects with no liver metastasis and <= to 5.0 x ULN in participants with liver metastasis.
  • Total bilirubin <= to 1.5 x ULN (<= to 4 x ULN and direct bilirubin <= to 1.5 x ULN is acceptable for subjects with Gilbert's syndrome).
  • Male and female participants of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after last investigational drug dose received.
  • All female participants of childbearing potential must each have a negative pregnancy test (serum or urine) result before initiating study treatment.
  • Participants must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an Independent Ethics Committee (IEC) or Institutional Review Board (IRB)-approved informed consent form (ICF) (including HIPAA authorization, if applicable) before performance of any study specific procedures or tests.

Критерии невключения

  • Prior therapy with an Epidermal Growth Factor Receptor (EGFR) inhibitor.
  • History of malignancy other than CRC, unless there is an exception that the malignancy has been cured and no tumor-specific treatment for the malignancy has been administered within the 5 years prior to initiation of study treatment (participants with a history of basal cell carcinoma or benign tumor of cervix can be enrolled if diagnosis and treatment occurred less than 3 years prior to randomization).
  • Anticipation of need for a major surgical procedure or radiation therapy (RT) during the study.
  • Treatment with chemotherapy, radiotherapy, surgery, immunotherapy, biological therapy, or any other investigational anticancer agent within 4 weeks prior to start of study treatment.
  • History of cardiac disease:
  • Congestive heart failure defined as Class II to IV per New York Heart Association (NYHA) classification.
  • Active coronary artery disease (CAD).
  • Previously diagnosed bradycardia or other cardiac arrhythmia defined as Grade 2 or higher according to NCI CTCAE, version 4.0, or uncontrolled hypertension.
  • Myocardial infarction that occurred within 6 months prior to start of study treatment (myocardial infarction that occurred greater than 6 months before the start of study treatment is permitted).
  • Malabsorption syndrome, chronic diarrhea (lasting greater than 4 weeks), inflammatory bowel disease, or partial bowel obstruction.
  • Known metastatic brain or meningeal tumors, unless the participant is greater than 6 months from definitive therapy, has a negative imaging study within 4 weeks of first dose of study treatment, and is clinically stable (no concomitant therapy, including supportive therapy with steroids or anticonvulsant medications) with respect to the tumor at the time of first dose of study treatment.
  • Uncontrolled seizure disorder, spinal cord compression, or carcinomatous meningitis.
  • Pericardial or pleural effusion (eg, requiring drainage) or pericardial involvement with the tumor. Participants with minimal pleural effusion may be eligible upon request by Investigator and approval by Sponsor.
  • Clinically significant active infection that requires antibiotic therapy.
  • Previous administration of ARQ 197.
  • Substance abuse or medical, psychological or social conditions that may, in the opinion of the Investigator, interfere with the participant's participation in the clinical trial or evaluation of the clinical trial results.
  • Any condition that is unstable or that could jeopardize the safety of the subject and the participant's protocol compliance including known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
  • Inability to swallow oral medications.
  • Pregnant or nursing females.

Источник: ClinicalTrials.gov, NCT01075048 · запись обновлена в реестре 8 апреля 2021.

Дизайн и результаты

ДизайнРандомизированное, двойное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)131
Что измеряют — первичные конечные точки (2), вторичных — 5
  • Progression-Free Survival (PFS) Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer With Wild-Type K-ras Oncogene (KRAS) Who Have Received Front-Line Systemic Therapy — Baseline up to 80 weeks postdose
  • Progression-Free Survival (PFS) Using Computed Best Response Following Treatment With Tivantinib (ARQ 197) in Combination With Irinotecan and Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Received Front-Line Systemic Therapy — Baseline up to 80 weeks postdose

Цель исследования

ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the safety, tolerability, and efficacy of ARQ 197, define the recommended dose for Phase 2.

After the recommended dose is determined for Phase 2, participants receive study drug or placebo with irinotecan and cetuximab.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01075048 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.